Elicio Therapeutics
Small biotech developing lymph-node-targeted KRAS vaccines for pancreatic and colorectal cancer.
ELI-002 7P (amphiphile mKRAS vaccine); AMPLIFY-7P phase 2 missed its primary endpoint in June 2026; phase 3 strategy being refined.
Pages like this
not linked directly; found by shared links- TrialAMPLIFY-7P
Shares ELI-002 7P, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeaA guaranteed purchase prize for the first drug against a named hard target
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.
- ProductMRTX1133
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeamRNA-delivered MYC decoy proteins instead of MYC inhibitors
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.
- InstitutionLaura and Isaac Perlmutter Cancer Center at NYU Langone Health
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.
- ProductElironrasib
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.
- TrialRASolute 302
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.